Q3 2024 · 13F-HR
RTW INVESTMENTS, LPholdings as filed
Filed 2024-11-14 · accession 0001493152-24-045409
$6.91B
Reported value
68
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $423.1M | 6.12% | 1,993,687 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $376.5M | 5.45% | 4,189,557 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $373.5M | 5.40% | 8,132,870 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $354.8M | 5.13% | 654,430 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $329.2M | 4.76% | 2,593,323 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $326.7M | 4.73% | 17,687,772 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $274.3M | 3.97% | 7,393,127 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $244.9M | 3.54% | 6,818,641 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $244.2M | 3.53% | 5,426,112 | Common | SOLE |
| 116794108 | BRKR | BRUKER CORP | $240.4M | 3.48% | 3,481,119 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $238.9M | 3.46% | 3,272,008 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $210.8M | 3.05% | 13,707,506 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $208.3M | 3.01% | 4,169,393 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $200.3M | 2.90% | 44,111,916 | Common | SOLE |
| 574795100 | MASI | MASIMO CORP | $195.0M | 2.82% | 1,462,400 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $186.2M | 2.69% | 6,654,033 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $169.8M | 2.46% | 5,919,435 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $159.3M | 2.31% | 2,712,096 | Common | SOLE |
| 70975L107 | PEN | PENUMBRA INC | $154.6M | 2.24% | 795,750 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $151.6M | 2.19% | 4,869,798 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $143.7M | 2.08% | 2,721,158 | Common | SOLE |
| 863667101 | SYK | STRYKER CORPORATION | $143.4M | 2.07% | 396,921 | Common | SOLE |
| 750491102 | RDNT | RADNET INC | $125.5M | 1.82% | 1,808,604 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $114.5M | 1.66% | 2,645,703 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $114.1M | 1.65% | 10,000,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $112.2M | 1.62% | 3,412,486 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $109.3M | 1.58% | 1,968,002 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $95.8M | 1.39% | 3,258,360 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $75.6M | 1.09% | 4,098,955 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $68.5M | 0.99% | 2,782,329 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $57.2M | 0.83% | 4,652,285 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $54.6M | 0.79% | 7,378,548 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $50.7M | 0.73% | 1,344,074 | Common | SOLE |
| 377322102 | GKOS | GLAUKOS CORP | $50.3M | 0.73% | 386,291 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $48.1M | 0.70% | 3,787,347 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $47.6M | 0.69% | 1,135,256 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $45.4M | 0.66% | 1,850,648 | Common | SOLE |
| 68572M106 | OBIO | ORCHESTRA BIOMED HLDGS INC | $42.2M | 0.61% | 8,206,159 | Common | SOLE |
| 78667J108 | SG7 | SAGE THERAPEUTICS INC | $40.4M | 0.58% | 5,591,700 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $30.0M | 0.43% | 14,946,420 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $28.6M | 0.41% | 1,705,960 | Common | SOLE |
| 88023B103 | TEM | TEMPUS AI INC | $22.6M | 0.33% | 400,000 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $22.3M | 0.32% | 3,327,129 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $20.5M | 0.30% | 863,389 | Common | SOLE |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $19.8M | 0.29% | 3,261,496 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $19.1M | 0.28% | 741,656 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $18.3M | 0.26% | 666,667 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $16.8M | 0.24% | 1,454,273 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $16.4M | 0.24% | 786,353 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $12.4M | 0.18% | 1,133,787 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $11.6M | 0.17% | 575,000 | Common | SOLE |
| 88025U109 | TXG | 10X GENOMICS INC | $11.4M | 0.16% | 502,856 | Common | SOLE |
| 4525EP101 | VTLUSD | IMMUNIC INC | $7.5M | 0.11% | 4,567,717 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $7.4M | 0.11% | 742,500 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $7.4M | 0.11% | 900,000 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $6.3M | 0.09% | 200,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $5.5M | 0.08% | 125,000 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $4.9M | 0.07% | 3,256,102 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $4.8M | 0.07% | 978,310 | Common | SOLE |
| 30068X103 | XGN | EXAGEN INC | $4.7M | 0.07% | 1,511,866 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $3.7M | 0.05% | 350,000 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $2.3M | 0.03% | 148,844 | Common | SOLE |
| 02008G102 | — | ALLURION TECHNOLOGIES INC | $2.3M | 0.03% | 3,697,549 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $1.7M | 0.02% | 635,276 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $799,500 | 0.01% | 50,000 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $540,151 | 0.01% | 209,361 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $49,300 | 0.00% | 10,000 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $22,575 | 0.00% | 350,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.